Top 10 Sales KPIs for Commercial Veterinary Practice Sales in 2027

1. Corporate Contract Attach Rate

Corporate contract attach rate ranks first because it is the single largest determinant of territory revenue durability in 2027, with Mars Veterinary Health alone controlling 18-22% of US small-animal revenue and consolidators collectively at 32-40%. Manufacturers target 65-80% of revenue under signed MSAs, while distributors target 55-70%. Below 50% attach rate, a territory is exposed to single-clinic churn every time a corporate buys an independent.

This KPI is for national account directors and regional VPs managing territory risk, not for field reps optimizing daily call routes. It trades away short-term independent-clinic relationship depth for long-cycle HQ-level negotiation that takes 6-9 months. It sits above formulary inclusion rate because a signed MSA locks volume before a single detail call happens.

2. Formulary Inclusion Rate

Formulary inclusion rate ranks second because a SKU absent from a practice's PIMS formulary cannot be auto-suggested at dispensing, forfeiting 4-7x the share of any non-formulary product. Category leaders target 60%+ inclusion within 90 days of first detail, while me-too parasiticides or generic NSAIDs realistically hit 35-45%. Apoquel-class novel therapeutics have exceeded 80% inclusion in under 60 days in high-performing territories.

This KPI is for field reps and clinical liaisons who control the 90-day post-detail window, not for finance teams tracking quarterly revenue. It trades away broad trial-order volume for narrow, deep penetration in target practices. It ranks below corporate contract attach rate because an MSA without formulary execution still leaks share at the dispensing moment.

3. Script Volume Per Vet

Script volume per vet per month ranks third because it is the cleanest diagnostic of whether a DVM is actually prescribing your product versus a competitor. Parasiticides benchmark at 25-40 doses per DVM monthly, atopic dermatitis therapeutics at 8-15 scripts, therapeutic diets at 12-22 bags, and livestock protocols at 4-9 per account. A DVM below half the category benchmark is either prescribing a rival or running a low-acuity practice.

This KPI is for territory managers and sales ops analysts who pull PIMS exports or distributor sell-through data. It trades away lagging revenue indicators for a leading prescription-behavior signal that predicts next quarter's volume. It ranks below formulary inclusion because a non-formulary product cannot generate scripts regardless of rep effort.

4. Gross Margin Split

Gross margin split ranks fourth because the Rx-OTC-equipment-diagnostics mix determines whether a territory hits its P&L even when revenue targets are met. Rx pharmaceuticals run 38-48% GM, OTC and consumables 18-26%, capital equipment 22-30% with 35-50% on service contracts, and diagnostics 28-42%. A territory at 70% OTC mix is not underperforming on revenue but is misaligned to the comp plan.

This KPI is for regional finance partners and commercial VPs who set territory targets and comp accelerators. It trades away simple revenue-attainment reporting for a mix-aware view that requires product-class tagging in the CRM. It ranks below script volume because margin mix follows prescription behavior rather than leading it.

5. Days Sales Outstanding

Days sales outstanding ranks fifth because working capital cost above 4% rates makes DSO a direct margin drain on distributor and manufacturer P&Ls. Blended benchmarks run 32-45 days, with corporate accounts on net-45 to net-60 contracts often hitting 50-65 days in practice, independents slipping from net-30 to 38-50 days, and cash accounts at 1-7 days. DSO above 55 days signals credit, billing-ops, and corporate-AP problems simultaneously.

This KPI is for credit managers and distribution finance teams, not for field reps whose call cadence does not move cash collection. It trades away sales-velocity focus for balance-sheet discipline that can slow new-account onboarding. It ranks below gross margin split because margin is set at the sale while DSO is recovered after it.

6. Route Density

Route density ranks sixth because productive face-to-face calls per rep per day is the operational ceiling on territory coverage and the earliest warning sign of rep burnout or bad mapping. Distributor field reps benchmark at 12-18 calls daily in dense suburban territories and 6-10 in rural, manufacturer specialty reps at 5-8, companion-animal generalists at 8-12, and livestock reps at 3-6. Below benchmark traces to territory mapping, windshield time, or target-list quality.

This KPI is for district managers running ride-alongs and for ops teams deploying Maptive, Badger Maps, or Salesforce Maps. It trades away depth per call for breadth of coverage, which can dilute detail quality. It ranks below DSO because route efficiency affects revenue generation while DSO affects cash conversion.

7. Share of Voice

Share of voice ranks seventh because detailing minutes captured in a practice relative to competitors determines whether a rep visit converts to a prescription change. Category leaders target 35-45% SoV in their core category at high-decile accounts, while new entrants need 20-25% just to be remembered at the next dispensing decision. Below 15% SoV in a category with a competitive product means the rep visit is paid for but produces nothing.

This KPI is for marketing and sales-effectiveness teams who validate rep call notes against Animalytix or Vetsource Insights panels. It trades away precise attribution for a directional signal that is less robust in veterinary than in human pharma. It ranks below route density because call volume is the input and share of voice is the quality-adjusted output.

8. T+90 Reorder Rate

T+90 reorder rate ranks eighth because trial orders are a vanity metric while second orders within 90 days prove clinical adoption and protocol integration. Clinically differentiated products target 55%+ reorder, me-too products 35-45%, and anything below 30% signals a broken launch. Zoetis hit T+90 reorder rates above 75% on Librela and Solensia by pairing detail visits with in-clinic CE and patient-tracking apps.

This KPI is for product managers and launch teams who own the 90-day post-launch window, not for reps chasing first-trial SPIFs. It trades away launch-volume headlines for a harder adoption signal that exposes whether clinical results actually landed. It ranks below share of voice because reorder follows sustained detailing presence rather than preceding it.

9. Rep Retention

Rep retention ranks ninth because territory disruption from turnover costs roughly 0.6-1.1x annual quota in lost revenue and ramp time, making it a lagging indicator that destroys every other KPI when it falls. Established commercial organizations like Zoetis, Boehringer, Merck, Elanco, Patterson, and MWI target 88%+ voluntary retention, the industry median including smaller specialty companies is 80-85%, and below 75% signals comp-plan, manager, or territory-design failure.

This KPI is for HR business partners and commercial VPs who own comp design and territory architecture, not for field reps themselves. It trades away short-term cost savings from low base salaries for long-term revenue stability that requires investment in retention. It ranks below T+90 reorder because retention is a structural enabler rather than a direct sales output.

10. New Product Trial Velocity

New product trial velocity ranks tenth because first-trial order count within 60 days of launch is the earliest directional signal of rep activity and target-list quality, even though it is a weaker predictor than T+90 reorder. A launch generating 400 trial orders in 60 days across a 200-rep field force suggests roughly 2 trials per rep, which is below the 4-6 per rep benchmark for a well-supported companion-animal launch.

This KPI is for launch teams and sales ops analysts who need a leading indicator before the 90-day reorder window closes. It trades away adoption quality for speed of market entry, which can create negatively predisposed practices if reorder fails. It ranks below rep retention because trial activity depends on a stable, trained field force to execute.

How we ranked these

We ranked the nine KPIs by weighting revenue impact, controllability, and measurement reliability. Corporate contract attach rate and formulary inclusion received the highest weights because they directly gate 60–80% of addressable revenue. Script volume per vet, gross margin split, and T+90 reorder rate followed, as they reveal product adoption and profitability. DSO, route density, share of voice, and rep retention were weighted lower but still critical for operational health.

We deliberately ignored vanity metrics like total call volume, raw trial order counts, and territory revenue without margin context. These inflate activity without proving adoption or profitability. We also excluded human-pharma-specific KPIs such as e-detail completion rates and speaker program attendance, which do not translate to veterinary buying behavior. Finally, we omitted lagging indicators like annual quota attainment because they arrive too late to drive corrective action.

What to look for

When choosing between these KPIs, prioritize those that directly influence cash flow and customer retention. Corporate contract attach rate and formulary inclusion are non-negotiable because they lock in recurring revenue and prevent competitor substitution. T+90 reorder rate and script volume per vet reveal whether your product is actually being used, not just trialed. DSO and rep retention protect working capital and territory stability.

Ignore any KPI that cannot be pulled from PIMS, distributor sell-through, or CRM within 30 days.

The most common mistake buyers make is adopting a KPI dashboard that looks comprehensive but lacks actionable triggers. They track nine metrics monthly, yet no one owns the gap-closing sprint when a metric falls below benchmark. Another error is copying a Zoetis or Mars scorecard without adjusting for company size, species mix, or distribution model. A $50M specialty parasiticide company cannot run the same KPI thresholds as a $9B diversified animal health leader.

Always customize thresholds to your segment and comp plan.

Related questions

What is a good corporate contract attach rate for veterinary sales?

Manufacturers target 65–80% of territory revenue under master services agreements with consolidators like Mars, NVA, or IVC. Distributors aim for 55–70%. Below 50% leaves you exposed to churn when a corporate buys an independent practice. Measure contracted volume monthly in CRM and track new versus renewal dollars separately.

How do you measure formulary inclusion rate in veterinary practices?

Pull PIMS exports from AVImark, ImproMed, Cornerstone, or ezyVet to see if your SKU appears on the active formulary. Target 60%+ inclusion within 90 days for a category leader. Non-formulary products lose 4–7x share because the PIMS cannot auto-suggest them at dispensing.

What is a realistic script volume per veterinarian per month?

Parasiticides like Bravecto or Simparica Trio should hit 25–40 doses per DVM monthly. Atopic dermatitis drugs like Apoquel target 8–15 scripts. Therapeutic diets run 12–22 bags. Vaccines track wellness visits at 18–28 doses. Livestock therapeutics like Draxxin average 4–9 protocols per account.

Why does DSO matter more in veterinary distribution than in human pharma?

Veterinary distributors operate on thinner margins and carry more inventory risk. A DSO above 50 days signals credit, billing, or corporate AP problems. With interest rates above 4%, every extra day of DSO directly erodes working capital. Independents pay net-30 but often slip to 38–50 days.

What is a healthy route density for veterinary sales reps?

Distributor reps should hit 12–18 calls per day in dense territories and 6–10 in rural areas. Manufacturer specialty reps average 5–8 deeper detail calls. Companion-animal generalists run 8–12. Livestock reps do 3–6 due to drive time and on-farm protocol work. Below benchmark usually means bad territory mapping.

How do you calculate share of voice for veterinary detailing?

Pull rep call notes from Salesforce or Veeva and calculate the percentage of total detail minutes in a practice that go to your products versus competitors. Category leaders target 35–45% share of voice. New entrants need 20–25% just to be remembered. Below 15% means your rep visit is wasted.

What T+90 reorder rate signals a successful veterinary product launch?

Aim for 55%+ reorder within 90 days for a clinically differentiated product. Me-too products realistically hit 35–45%. Below 30% means the launch is broken—either clinical results are not landing, pricing is wrong, or reps sold novelty without protocol adoption. Zoetis hit 75%+ on Librela and Solensia.

What rep retention rate should veterinary commercial leaders target?

Established animal health organizations like Zoetis, Boehringer, Merck, and Patterson target 88%+ voluntary retention. The industry median including smaller specialty companies is 80–85%. Below 75% signals comp plan, manager, or territory design problems. Territory disruption costs 0.6–1.1x annual quota in lost revenue and ramp time.

FAQ

How much of veterinary sales is controlled by corporate consolidators in 2027?

Roughly 32–40% of US small-animal practice revenue runs through corporate-owned hospitals. Mars Veterinary Health alone controls 18–22%, with NVA, IVC Evidensia, Thrive, Pathway, Southern Veterinary Partners, AmeriVet, and Encore making up the rest. Equine and production-animal segments remain largely independent, so adjust coverage models accordingly.

What is the right ratio of generalist to specialty reps for a mid-size animal health company?

For a $200M–$800M animal health business, a workable mix is 65–75% generalist field reps and 25–35% specialty reps covering dermatology, pain, oncology, parasitology, or livestock production. Below $200M you cannot afford true specialty coverage and should pair generalists with regional clinical liaisons. Above $1B you see fully matrixed specialty teams like Zoetis runs.

Which PIMS systems matter most for formulary tracking in veterinary sales?

AVImark, ImproMed Infinity, Cornerstone, ezyVet, and IDEXX Neo cover most US small-animal practices. Pulse Veterinary Technologies and ProVet Cloud are growing in cloud-first clinics. Corporate-owned hospitals may run custom stacks, so verify directly with their procurement team rather than assuming standard PIMS access. Formulary data feeds vary by system and contract.

How do you negotiate with Mars Veterinary Health or other large consolidators?

Engage 6–9 months before contract renewal at the central procurement office, not the hospital level. Bring clinical outcome data, margin-stack analysis, and supply-chain reliability proof. Mars procurement runs through Vernon Hills and McLean. Without a national accounts team, manufacturers get locked out of 18–22% of US small-animal revenue before the rep even knows a renewal is happening.

Why do veterinary sales reps need margin math on every detail call?

The prescriber is often the practice owner who pays the invoice. If your product delivers lower dispensing margin than a competitor, the DVM will nod at your clinical data and keep prescribing the cheaper alternative. Every detail call should include a one-page P&L impact sheet comparing your product to the realistic competitor on margin per dispense.

What is the biggest mistake in veterinary KPI dashboards?

Tracking too many metrics without assigning an owner to close gaps. A dashboard with nine KPIs reviewed monthly but no sprint trigger when a metric falls below benchmark is just slides. Another error is copying a Zoetis or Mars scorecard without adjusting thresholds for company size, species mix, and distribution model. Customize to your segment.

How do you split KPIs between livestock and companion animal sales teams?

Split comp plans, call cadence targets, and KPI thresholds at the species line. A feedlot rep with three $4M accounts looks bad on calls per day but great on margin per call. A companion rep with 80 $40k accounts looks the opposite. Running one funnel across both mis-comps the team and hides true performance.

What reporting cadence works best for veterinary sales KPIs?

Daily call reports and route density. Weekly sell-through reconciliation and T+30 reorder checks. Monthly script volume, gross margin split, DSO, and share of voice. Quarterly QBRs with national accounts, finance, and supply chain. The cadence must produce decisions, not just slides. If no one acts on a weekly flag, the cadence is too slow.

How do you fix a veterinary product launch with low T+90 reorder rates?

Run a structured review of every SKU launched in the trailing six months. If reorder is below 35%, diagnose whether clinical results are not landing, pricing is wrong, or reps sold novelty without protocol adoption. Reformulate the rollout with in-clinic CE, patient-tracking tools, and SPIFs tied to reorder rather than trial order volume.

What is the 30/60/90 day plan for a new veterinary sales leader?

Days 1–30: map territory ownership, audit corporate MSAs, and baseline all nine KPIs. Days 31–60: fix the largest KPI gap with a four-week sprint and begin MSA renewal conversations. Days 61–90: lock reporting cadence, adjust SPIFs to drive lagging behaviors, and set annual targets split by species and channel.

Sources

• https://www.zoetis.com
• https://www.boehringer-ingelheim.com/animal-health
• https://www.merck-animal-health.com
• https://www.elanco.com
• https://www.pattersonvet.com
• https://www.mwiah.com
• https://www.covetrus.com
• https://www.marsveterinary.com
• https://www.nva.com
• https://www.ivcevidensia.com

Related on PULSE

• More sales kpis for commercial veterinary practice sales rankings and buying guides
• PULSE Tools and calculators
• Everything on PULSE RevOps